SCENESSE Trademark

Trademark Overview


On Tuesday, February 13, 2018, a trademark application was filed for SCENESSE with the United States Patent and Trademark Office. The USPTO has given the SCENESSE trademark a serial number of 79229902. The federal status of this trademark filing is PARTIAL SECTION 71 & 15 ACCEPTED AND ACKNOWLEDGED as of Monday, July 14, 2025. This trademark is owned by Clinuvel Pharmaceuticals Limited. The SCENESSE trademark is filed in the Cosmetics & Cleaning Products and Pharmaceutical Products categories with the following description:

Pharmaceutical preparations, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for skin care and for treating skin and skin relating conditions and disorders; medicated sun tanning preparations for pharmaceutical purposes, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; chemical and biological preparations, substances, reagents and compounds, namely, drug delivery agents consisting of compounds that facilitate the delivery of pharmaceuticals which are based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, and pharmaceutical preparations based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for use in dermatology, for skin care, for the treatment of skin disorders, for the protection of the dermis and epidermis used in the manufacture, delivery and storage of pharmaceuticals, drugs and diagnostic preparations

[ Cosmetic preparations for skin care, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; non-medicated sun tanning preparations based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; cosmetics for tanning the skin, namely, cosmetics for tanning the skin based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, and preparations for tanning without sunlight based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide ]
scenesse

General Information


Serial Number79229902
Word MarkSCENESSE
Filing DateTuesday, February 13, 2018
Status708 - PARTIAL SECTION 71 & 15 ACCEPTED AND ACKNOWLEDGED
Status DateMonday, July 14, 2025
Registration Number5724241
Registration DateTuesday, April 16, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 29, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for skin care and for treating skin and skin relating conditions and disorders; medicated sun tanning preparations for pharmaceutical purposes, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; chemical and biological preparations, substances, reagents and compounds, namely, drug delivery agents consisting of compounds that facilitate the delivery of pharmaceuticals which are based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, and pharmaceutical preparations based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, for use in dermatology, for skin care, for the treatment of skin disorders, for the protection of the dermis and epidermis used in the manufacture, delivery and storage of pharmaceuticals, drugs and diagnostic preparations
Goods and Services[ Cosmetic preparations for skin care, based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; non-medicated sun tanning preparations based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide; cosmetics for tanning the skin, namely, cosmetics for tanning the skin based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide, and preparations for tanning without sunlight based on analogues of melanocyte-stimulating hormone (MSH), in particular afamelanotide ]

Classification Information


International Class003 - Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices.
US Class Codes001, 004, 006, 050, 051, 052
Class Status CodeG - NOT AVAILABLE
Class Status DateMonday, July 14, 2025
Primary Code003
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 10, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameClinuvel Pharmaceuticals Limited
Party Type31 - New Owner After Registration
Legal Entity Type98 - Unknown
AddressAU

Party NameClinuvel Pharmaceuticals Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressMelbourne VIC 3000
AU

Party NameClinuvel Pharmaceuticals Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressAU

Party NameClinuvel Pharmaceuticals Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressAU

Trademark Events


Event DateEvent Description
Thursday, April 5, 2018SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Monday, April 9, 2018LIMITATION FROM ORIGINAL APPLICATION ENTERED
Tuesday, April 10, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, April 14, 2018APPLICATION FILING RECEIPT MAILED
Tuesday, May 29, 2018ASSIGNED TO EXAMINER
Thursday, May 31, 2018NON-FINAL ACTION WRITTEN
Friday, June 1, 2018NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, June 7, 2018REFUSAL PROCESSED BY MPU
Thursday, June 7, 2018NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, June 29, 2018REFUSAL PROCESSED BY IB
Monday, December 3, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 3, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 4, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 5, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 26, 2018ASSIGNED TO LIE
Wednesday, January 9, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 9, 2019NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, January 9, 2019NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, January 11, 2019TOTAL INVALIDATION PROCESSED BY THE IB
Tuesday, January 29, 2019PUBLISHED FOR OPPOSITION
Tuesday, January 29, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, March 1, 2019NOTIFICATION PROCESSED BY IB
Tuesday, April 16, 2019REGISTERED-PRINCIPAL REGISTER
Tuesday, July 16, 2019FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, August 8, 2019FINAL DISPOSITION PROCESSED
Thursday, August 8, 2019FINAL DISPOSITION NOTICE SENT TO IB
Friday, September 13, 2019FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, November 14, 2019CHANGE OF NAME/ADDRESS REC'D FROM IB
Thursday, July 2, 2020INTERNATIONAL REGISTRATION RENEWED
Tuesday, April 16, 2024COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Wednesday, April 16, 2025TEAS SECTION 71 & 15 RECEIVED
Monday, July 14, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, July 14, 2025REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Monday, July 14, 2025NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Thursday, December 18, 2025CHANGE OF NAME/ADDRESS REC'D FROM IB